Media Release, May 14, 2018: “US President Donald Trump’s policy to end “freeloading” and force trading partners to increase prices they pay for US pharmaceutical exports is a direct threat to Australia’s policy of ensuring affordable medicines through our Pharmaceutical Benefits Scheme,” AFTINET Convener Dr Patricia Ranald said today.
“This policy results from the US pharmaceutical companies absurd and unproven argument that if other governments abandon their affordable medicine policies and agree to higher prices, the companies would then lower their prices in the US. Both Canada and New Zealand have strongly rejected this push. There has so far been no reported response from the Turnbull government. We call on the government to reject this policy,” said Dr Ranald.